Alnylam Pharmaceuticals (ALNY) Net Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,043.00 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 29,636.00 |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -68,847.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,208.00 |
| Mar 31, 2026 | 7,849.00 |
| Dec 31, 2025 | 2,429.00 |
| Sep 30, 2025 | 4,571.00 |
| Jun 30, 2025 | -678.00 |
| Mar 31, 2025 | -4,750.00 |
| Dec 31, 2024 | 1,723.00 |
| Sep 30, 2024 | -4,196.00 |
| Jun 30, 2024 | 8,404.00 |
| Mar 31, 2024 | 4,119.00 |
| Dec 31, 2023 | 3,058.00 |
| Sep 30, 2023 | 17,327.00 |
| Jun 30, 2023 | 3,679.00 |
| Mar 31, 2023 | 5,817.00 |
| Dec 31, 2022 | 3,804.00 |
| Sep 30, 2022 | -4,458.00 |
| Jun 30, 2022 | -3,744.00 |
| Mar 31, 2022 | 10.00 |
| Dec 31, 2021 | 4,893.00 |
| Sep 30, 2021 | 9,226.00 |